Physician profile
John S King
NPI 1255350021
$3,065.10
in general payments reported to CMS, 2019-2025
19 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $136 · 2021: $249 · 2022: $372 · 2023: $627 · 2024: $600 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $880.05 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $486.56 | 2019-2025 | |
| Allergan, INC. | $369.37 | 2019-2021 | |
| Alimera Sciences, INC. | $274.40 | 2021-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $259.23 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $143.37 | 2022-2025 | Vabysmo |
| Optos, INC. | $100.01 | 2022 | |
| Astellas Pharma US INC | $96.95 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $95.27 | 2023 | Xipere, Visudyne |
| Novartis Pharmaceuticals Corporation | $78.59 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $63.97 | 2025 | Yutiq, Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $53.02 | 2024-2025 | Acthar |
| Vyera Pharmaceuticals, LLC | $35.74 | 2020 | |
| Spark Therapeutics, INC. | $33.79 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $28.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tandem Diabetes Care, INC. | $17.77 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eyepoint US, INC. | $15.76 | 2022 | |
| Abiomed | $13.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.